Cerebral Therapeutics™, Inc. (Cerebral), a clinical-stage pharmaceutical company developing specialty medications for uncontrolled neurological diseases, announced today the appointment of industry veteran John Foster as President and Chief Operating Officer. Mr. Foster will utilize his extensive executive management experience leading companies, developing products and navigating the FDA regulatory environment to expand the strategic breadth and depth of the Cerebral executive management team.
Cerebral Therapeutics™, a clinical-stage pharmaceutical company developing specialty medications for uncontrolled neurological diseases, announced today that the Company will present at the Antiepileptic Drug and Device (AEDD) Trials XV conference, which is held every two years and is sponsored by The Epilepsy Study Consortium in collaboration with the University of Pennsylvania and the Epilepsy Foundation.
A currently approved epileptic drug to treat seizures has been modified by a University of Colorado Anschutz Medical Campus professor and is currently being used in a clinical trial in Australia for medically refractory epilepsy.
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS, April 3, 2019